Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/8/2026, 12:00:00 AM
Merck and Gilead announced on June 8, 2026, that two Phase 3 trials (ISLEND-1 and ISLEND-2) for their investigational once-weekly oral HIV treatment, islatravir/lenacapavir, met their primary efficacy endpoints. Internal analysis estimates a moderate positive impact (~5%) as it validates a new treatment regimen, expected.
Korean Translation
머크와 길리어드는 2026년 6월 8일, 개발 중인 주 1회 경구용 HIV 치료제 이슬라트라비르/레나카파비르의 3상 임상 2건(ISLEND-1, ISLEND-2)이 1차 유효성 평가변수를 충족했다고 발표함. 내부 분석 결과 새로운 치료 요법의 유효성 입증으로 약 5%의 긍정적 주가 영향이 예상됨.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target is scheduled to report its Q2 2026 financial results on August 19, 2026, with analysts forecasting EPS around $2.21-$2.25. Medium importance is assigned as upcoming earnings are significant catalysts with expected price movement between 5-10%. This event is scheduled.
8/19/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
Second quarter 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release on August 6, 2026, with an estimated ~1% price impact, scheduled.
8/6/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife is scheduled to release its Q2 2026 financial results after the market closes on August 5, 2026; due to typical earnings volatility, a price impact of at least 5% is expected.
8/5/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release scheduled, with analysts forecasting EPS of approximately $1.66. As this is a significant quarterly update, a medium impact is forecasted.
8/3/2026, 12:00:00 AM
Exxon Mobil Corp (XOM) · Earnings Release
Second-quarter 2026 earnings release scheduled for July 31, 2026. Low importance is based on the expected market reaction to a standard earnings release. Analysts forecast earnings per share of approximately $3.76 estimated.
7/31/2026, 12:00:00 AM